Sector News

Perrigo CEO: Think Mylan’s buyout will come easily? Think again

August 7, 2015
Life sciences
Perrigo has stayed quiet since Teva dropped its hostile pursuit of Mylan, choosing instead to snap up Allergan’s generics business for $40.5 billion. Mylan’s shares plummeted on that news. And now, Perrigo has broken its silence–and the word isn’t what Mylan wants to hear.
 
Perrigo CEO Joseph Papa stuck to his company’s prior stance that Mylan’s $205-per-share bid “substantially undervalues” its business–and “the market movement following Teva’s announcement last week only reinforced” that conviction, he said during the company’s Q2 earnings call.
 
And if Mylan shareholders vote–at a special meeting later this month–to push forward with the Perrigo deal anyway? “If they proceed with a tender offer for Perrigo, this will not be the easy path that some are painting it to be,” he said, pointing out that the bar for success in the tender offer process is 80% of all outstanding Perrigo shares. ” … We’ll make a strategic decision with the board about what’s the right thing to do for the company,” he said.
 
The way some analysts see it, that’s still a big “if.” As Leerink Partners’ Jason Gerberry wrote in a recent note to investors, Mylan would have to bring its bid to about $230 per Perrigo share to make an “acceptable” offer for its target. And even if it can muster that, the potential tie-up “does not appear to create any value at prices above $205,” Cowen & Co. analyst Ken Cacciatore wrote late last month.
 
Meanwhile, Mylan topped Q2 earnings forecasts Thursday, posting EPS of 91 cents–2 cents better than analysts expected. Revenue of $2.37 billion fell short of analysts’ $2.39 billion forecast, however, despite year-over-year growth of 29%.
 
By Carly Helfand
 

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”